The U.S. Food and Drug Administration (FDA) has approved Genentech’s TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. This approval marks Genentech’s second approval for stroke, reinforcing its dedication to advancing stroke care as the developer of the only two FDA-approved medicines for AIS: TNKase and Activase (alteplase). Genentech is a member of the Roche Group. TNKase is delivered as a single five-second intra...